Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paluratide
- Development stage
- Discontinued
- Lead developer
- Chugai Pharmaceutical
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Paluratide (LUNA18) is an orally available cyclic peptide and a first-in-class Ras protein inhibitor developed for the treatment of solid tumors. It selectively binds to and inhibits Ras proteins—including KRAS, NRAS, and HRAS—by disrupting the protein-protein interaction between inactive RAS and guanine nucleotide exchange factors (GEFs). This inhibition blocks Ras-dependent signaling pathways that drive tumor cell proliferation in cancers with overexpressed or mutated RAS genes. Paluratide demonstrates oral bioavailability (21–47%) without special formulation and has shown potent activity in preclinical models. The drug is currently in Phase I clinical trials for patients with locally advanced or metastatic solid tumors[1][3][4][5][6][7].
- Brand names
- LUNA18 CapsuleLUNA-18 CapsuleLUNA 18 Capsule
- Other names
- RAS inhibitor LUNA18paluratide
02
Targets
HRAS (H-Ras protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)NRAS (Neuroblastoma RAS viral oncogene homolog)
Beyond the preview
Go deeper on paluratide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paluratide.